Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide oral liquid in children and adolescents with autism spectrum disorder
2017-004419-38Phase 3Unknown
- Sponsor
- Servier
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Bumetanide 0.5 mg BID with Placebo (2 arms). Primary endpoint: CARS2 total raw score. Status: unknown.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2017-004419-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004419-38.